Invivyd Q1 net product revenue $13.7M (+22% YoY); net loss $41.4M; VYD2311 data delayed to Q3 2026

Invivyd, Inc.

Q1 2026 PEMGARDA net product revenue $13.7M, up 22% YoY vs $11.3M.
Net loss $41.4M ($0.13/sh) vs $16.3M ($0.14/sh) in Q1 2025; R&D expense rose to $30.7M.
Cash $184.2M at Mar 31; raised ~$20M via ATM in Apr 2026, extending runway through VYD2311 launch.
DECLARATION trial upsized by ~500 subjects; top-line data now expected in Q3 2026 (shift from mid-year).
IDMC reduced VYD2311 post-dose monitoring from 2 hours to 30 min; in vitro neutralization vs BA.3.2.2 confirmed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.